CST Study Targeting Tau and Amyloid Pathology Published in Molecular Therapy

A new study published in Molecular Therapy reports the therapeutic effects of catestatin (CST) in preclinical models of neurodegenerative disease.

Jati S, et al. (2026). Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition. Molecular Therapy. Epub ahead of print. doi: 10.1016/j.ymthe.2026.09.022. PMID: 42768750.

The study provides preclinical evidence that CST acts on multiple pathological processes associated with Alzheimer's disease and related neurodegenerative disorders, including tau and amyloid pathology, neuroinflammation, and associated functional deficits. The findings further support development of CST as a potential multi-pathway peptide therapeutic for neurodegenerative disease.

CgA Therapeuticals Receives NIH/NIDDK SBIR Phase I Award for Gastroparesis

CgA Therapeuticals, Inc. has received a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) for the project, “Peptide and Peptidomimetic Therapy for Gastroparesis” (1R43DK148298-01).

The program will advance catestatin (CST) and next-generation CST peptidomimetics as potential therapeutics for gastroparesis through preclinical efficacy, pharmacology, pharmacokinetic, and therapeutic-development studies. The award represents an important milestone in CgA Therapeuticals' efforts to translate CST biology into novel treatments for gastrointestinal disorders.

Study Reveals a Role for Catestatin in Restoring Cardiac Metabolic Flexibility

A study published in Communications Biology reports that catestatin restores cardiac metabolic flexibility and enhances mitochondrial function in preclinical models, providing new insights into the cardiometabolic actions of CST and its potential therapeutic applications.

Kal S, et al. (2026). Catestatin restores cardiac metabolic flexibility and enhances mitochondrial function. Communications Biology. 9(1):1110.

This work expands the therapeutic foundation for CST in cardiovascular and metabolic disease and provides additional mechanistic support for development of CST-based therapeutics.

AI-Guided Study Establishes a Murine Model of Asymptomatic Alzheimer's Disease

A study published in Acta Neuropathologica Communications reports the AI-guided discovery and experimental characterization of a murine model of asymptomatic Alzheimer's disease (AsymAD).

Using Boolean implication network analysis of human Alzheimer's disease datasets followed by experimental validation, the study identifies molecular signatures and biological mechanisms associated with cognitive resilience despite Alzheimer's disease-related pathology.

Jati S, et al. (2026). AI-guided discovery of a murine model of asymptomatic Alzheimer's disease. Acta Neuropathologica Communications. 14(1):110.

The findings provide a new experimental framework for investigating mechanisms of resilience to Alzheimer's disease pathology and identifying potential therapeutic targets for preserving cognitive function.

CgA Therapeuticals Executes Exclusive Therapeutic License with UC San Diego

CgA Therapeuticals entered into an exclusive license agreement with The Regents of the University of California, represented by UC San Diego, covering defined patent rights for specified therapeutic technologies.

The licensed intellectual property includes inventions spanning cardiometabolic disease, neurodegeneration and cognitive decline, and oncology, providing an important foundation for the continued development and potential commercialization of CST-based therapeutic technologies.